Yes.
The other thing that's important to recognize is that our pharmaceutical industry—in quotation marks—is all basically foreign-owned. In Europe we're talking about countries that are negotiating on behalf of large companies that see huge benefits in terms of their balance of payments.
Our balance of payments, as I mentioned, is now $7.5 billion in deficit, and it's going to increase. There's no evidence that the extension of patent protection in the TPP will in any way benefit us with regard to that. There's lots of evidence to suggest that our balance of payments will get much worse as a result of that and CETA.
I guess that's my frustration. Why can't we learn something from this?